Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 11/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16536339 | 0.92 | PDE1B (0.51) | PDE1BCNR1CNR2MAPTALDH1A1 | |
| SCHEMBL1592961 | 0.92 | PDE1B (0.53) | PDE1BCNR1CNR2MAPTALDH1A1 | |
| SCHEMBL23069164 | 0.89 | PDE1B (0.50) | PDE1BCNR1CNR2MAPTALDH1A1 | |
| SCHEMBL29872865 | 0.89 | PDE1B (0.50) | PDE1BCNR1CNR2MAPTALDH1A1 | |
| SCHEMBL2966796 | 0.88 | PDE1B (0.55) | PDE1BCNR1CNR2MAPTALDH1A1 | |
| SCHEMBL1585706 | 0.86 | PDE1B (0.57) | PDE1BCNR1CNR2MAPTALDH1A1 | |
| SCHEMBL1593021 | 0.86 | PDE1B (0.54) | PDE1BCNR1CNR2MAPTALDH1A1 | |
| SCHEMBL15999430 | 0.86 | PDE1B (0.54) | PDE1BCNR1CNR2MAPTALDH1A1 | |
| SCHEMBL1593023 | 0.85 | CNR1 (0.47) | PDE1BCNR1CNR2MAPTALDH1A1 | |
| SCHEMBL28431878 | 0.85 | CNR1 (0.47) | PDE1BCNR1CNR2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119654314-A | Heterocyclic amide and urea compounds as JAK2 inhibitors | 艾捷斯治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-111393433-B | Heterocyclic benzene sulfonamide compound and application thereof | 暨南大学 | 2021-07-30 | — | — | CN | disclosed |
| CN-111393433-A | Heterocyclic benzene sulfonamide compound and application thereof | 暨南大学 | 2020-07-10 | — | — | CN | disclosed |
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3039021-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015031613-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-2265610-A1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | JAK2, JAK1, JAK3 | PDE1B 2544/4885CNR1 3007/4885CNR2 2559/4885 |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | BRAF, RAF1, ARAF | PDE1B 370/4885CNR1 3221/4885CNR2 3546/4885 |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ERBB2, ERBB3, AADAC | PDE1B 1222/4885CNR1 980/4885CNR2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.